PGR and breast cancer: The progesterone receptor antagonist, RU486, blocked the effects of all progestins on pri-miR-190 expression. On the other hand, our study showed that both MPA (Figure 2A) and progesterone (data not shown) did not significantly affect primiR-190 expression in another PR-positive breast cancer cell line, BT-474 cells.